ID: ALA65032

Max Phase: Preclinical

Molecular Formula: C9H14N5O5P

Molecular Weight: 303.22

Molecule Type: Small molecule

Representations

Canonical SMILES:  NC1=NC2N=CC=NC2C(=O)N1CCOCP(=O)(O)O

Standard InChI:  InChI=1S/C9H14N5O5P/c10-9-13-7-6(11-1-2-12-7)8(15)14(9)3-4-19-5-20(16,17)18/h1-2,6-7H,3-5H2,(H2,10,13)(H2,16,17,18)

Standard InChI Key:  YRXRTCVDYBOKFL-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 303.22

Molecular Weight (Monoisotopic): 303.0733

AlogP: -1.85

#Rotatable Bonds: 5

Polar Surface Area: 150.17

Molecular Species: ACID

HBA: 7

HBD: 3

#RO5 Violations: 0

HBA (Lipinski): 10

HBD (Lipinski): 4

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 1.32

CX Basic pKa: 4.84

CX LogP: -1.71

CX LogD: -3.64

Aromatic Rings: 0

Heavy Atoms: 20

QED Weighted: 0.40

Np Likeness Score: 0.07

References

1. Holý A, Günter J, Dvoráková H, Masojídková M, Andrei G, Snoeck R, Balzarini J, De Clercq E..  (1999)  Structure-antiviral activity relationship in the series of pyrimidine and purine N-[2-(2-phosphonomethoxy)ethyl] nucleotide analogues. 1. Derivatives substituted at the carbon atoms of the base.,  42  (12): [PMID:10377214] [10.1021/jm9811256]

Source

Source(1):

• Scientific Literature